A5055882180- CAR-T cell therapy research
- Immune Cell Function and Interaction
- CRISPR and Genetic Engineering
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- T-cell and B-cell Immunology
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Anatomy and Medical Technology
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Lymphocytic Leukemia Research
- Surgical Simulation and Training
- Intracranial Aneurysms: Treatment and Complications
- Cancer Genomics and Diagnostics
- Histiocytic Disorders and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Neutropenia and Cancer Infections
- Vascular Malformations Diagnosis and Treatment
- Viral-associated cancers and disorders
- Glioma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Ubiquitin and proteasome pathways
- Cytomegalovirus and herpesvirus research
Seoul National University
2024
Washington University in St. Louis
2018-2023
University of Pennsylvania
2015-2021
University of Wisconsin Carbone Cancer Center
2020
University of Wisconsin–Madison
2018-2020
Pediatrics and Genetics
2019
Namseoul University
2019
University of Southern California
2011-2017
California University of Pennsylvania
2016
Southern California University for Professional Studies
2013
Chimeric antigen receptor (CAR) T cell therapy is routinely used to treat patients with refractory hematologic malignancies. However, a significant proportion of experience suboptimal CAR cytotoxicity and persistence that can permit tumor escape disease relapse. Here we show prototype pro-lymphoid growth factor able enhance efficacy. We demonstrate long-acting form recombinant human interleukin-7 (IL-7) fused hybrid Fc (rhIL-7-hyFc) promotes proliferation, cells in xenogeneic mouse models,...
Abstract T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden use CAR-T cells in pan malignancies, we developed an allogeneic “universal” CD2-targeting cell (UCART2), CD2 antigen deleted prevent fratricide, receptor removed GvHD. UCART2 demonstrated efficacy against T-ALL CTCL prolonged survival tumor-engrafted NSG mice vivo. evaluate impact on function, generated CD19 (UCART19)...
Targeting T cell malignancies with universal CD7-targeting chimeric antigen receptor cells (UCART7) can lead to profound immune deficiency due loss of normal and NK cells. While a small population endogenous CD7- exists, these are unlikely be able repopulate the entire repertoire after UCART7 treatment, as they limited in number proliferative capacity. To rescue UCART7, we created hematopoietic stem genetically deleted for CD7 (CD7-KO HSCs). CD7-KO HSCs were engraft immunodeficient mice...
The programmable nuclease technology CRISPR-Cas9 has revolutionized gene editing in the last decade. Due to risk of off-target editing, accurate and sensitive methods for characterization are crucial prior applying therapeutically. Here, we utilized a rhesus macaque model compare predictive values CIRCLE-seq, an vitro prediction method, with silico (ISP) based solely on genomic sequence comparisons. We use AmpliSeq HD error-corrected sequencing validate sites predicted by CIRCLE-seq ISP CD33...
OBJECTIVE AND IMPORTANCE: We describe a rare case of an extra-axial cavernoma the cerebellopontine angle without internal auditory canal involvement and with unusual appearance on preoperative magnetic resonance imaging (MRI). Only three cases cavernomas have been previously reported, none these reports included MRI. CLINICAL PRESENTATION: A young man presented subacute left facial hypesthesia chronic asymmetrical sensorineural hearing loss. MRI revealed mass, which was isointense T1-...
EPHB4, an ephrin type B receptor, is implicated in the growth of several epithelial tumors and a promising target cancer therapy; however, little known about its role hematologic malignancies. In this article, we show that EPHB4 highly expressed ∼30% acute myeloid leukemia (AML) samples. unbiased RNA interference screen primary samples, found drives survival subset AML cases. Knockdown inhibits phosphatidylinositol 3-kinase/AKT signaling, accompanied by reduction cell viability, which can be...
We recently developed a novel amine-reactive mass-defect-based chemical tag, dimethyl pyrimidinyl ornithine (DiPyrO), for quantitative proteomic analysis at the MS
Chimeric antigen receptor T (CART) cell therapy results in impressively high remission rates B neoplasms but is limited by the development of cytokine release syndrome (CRS). While use anti-IL6 antibody tocilizumab with or without steroids can reverse this syndrome, there concern that early immunosuppression could impair anti-tumor activity and therefore reserved for severe CRS. Ruxolitinib a JAK/STAT pathway inhibitor has resulted significant reduction inflammatory cytokines preclinical...
Object. The 11th rib extrapleural—retroperitoneal approach offers an alternative means for access to the thoracolumbar junction. It provides excellent operative exposure without need transgress diaphragm, resulting in less morbidity and reduced risk of pulmonary complications. This approach, however, has been dismissed by many surgeons offering unsubstantiated criticism that it affords limited access. Thus far, only technical descriptions procedure are available literature, documentation...
Chemo-refractory acute myeloid leukemia (AML) is associated with poor prognosis and treatment options are extremely limited. AML thought to arise due selection pressure of resistant clones from prior use chemotherapy or in some cases pre-exist properties the leukemic stem cells (LSC). CLEC12A (also known as CLL1) has previously been described being selectively over expressed LSCs. Successful modalities target eradicate LSC would overcome chemo-refractoriness represent a vertical advance...
We compared the three arms of MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), MPR maintenance (MPR-R)] to determine whether addition therapy for primary treatment multiple myeloma is cost-effective. used progression-free survival adverse event data from study analysis. Two novel measures cost-effectiveness termed Average Cumulative Cost per Patient (ACCP) Progression-Free Survivor (ACCPFS) were developed purpose this The ACCP was USD...
Abstract Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated profound results in hematologic malignancies but clinical efficacy the solid tumor setting not been observed. Barriers to entry and function may partially explain this observation. As tumors actively recruit myeloid cells, we hypothesized that macrophages have potential be a powerful cellular immunotherapeutic agent if properly activated redirected. We here describe development of CAR (CARMA), demonstrating...
The use of mass spectrometry for protein identification and quantification in cerebrospinal fluid (CSF) is at the forefront research efforts to identify explore biomarkers early diagnosis prognosis neurologic disorders. Here we implemented a 4-plex N,N-dimethyl leucine (DiLeu) isobaric labeling strategy longitudinal study aiming investigate dynamics children with B-cell acute lymphoblastic leukemia (B-cell ALL) undergoing chemotherapy. temporal profile CSF proteome during chemotherapy...